These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

107 related articles for article (PubMed ID: 10326149)

  • 41. Strategies for the management of acute myocardial infarction: selecting patients for thrombolytic therapy.
    Talbert RL
    Am J Health Syst Pharm; 1997 Nov; 54 Suppl 1():S9-16. PubMed ID: 9397232
    [TBL] [Abstract][Full Text] [Related]  

  • 42. [Thrombolysis: Reteplase as an innovative alternative].
    Z Kardiol; 1997 Oct; 86(10 Suppl):1-4. PubMed ID: 9403093
    [No Abstract]   [Full Text] [Related]  

  • 43. Systemic thrombolytic therapy of acute myocardial infarction?
    Collen D; Verstraete M
    Circulation; 1983 Aug; 68(2):462-5. PubMed ID: 6683133
    [No Abstract]   [Full Text] [Related]  

  • 44. [Structure of the natural plasminogen activator (t-PA) and of reteplase. Controversies on thrombolytic therapy. 45th yearly session of the American College of Cardiology. Orlando, Fla. March 1996].
    Dtsch Med Wochenschr; 1996; 121(36 Suppl Fur Praxis):1-8. PubMed ID: 9401482
    [No Abstract]   [Full Text] [Related]  

  • 45. The promise of new genetically engineered plasminogen activators.
    Cutler D; Bode C; Runge MS
    J Vasc Interv Radiol; 1995; 6(6 Pt 2 Suppl):3S-7S. PubMed ID: 8770835
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Reteplase in acute myocardial infarction.
    Busti AJ; Marshall KS; Hooper JS
    JAMA; 2004 May; 291(20):2429-30; author reply 2430. PubMed ID: 15161887
    [No Abstract]   [Full Text] [Related]  

  • 47. Pharmacokinetics and pharmacodynamics of lanoteplase (n-PA).
    Nordt TK; Moser M; Kohler B; Kübler W; Bode C
    Thromb Haemost; 1999 Sep; 82 Suppl 1():121-3. PubMed ID: 10695501
    [TBL] [Abstract][Full Text] [Related]  

  • 48. The concept of equivalence and its application to the assessment of thrombolytic effects.
    Hampton JR
    Eur Heart J; 1997 Dec; 18 Suppl F():F22-7. PubMed ID: 9447337
    [TBL] [Abstract][Full Text] [Related]  

  • 49. A characterization of myocardial infarction induced by thrombotic occlusion and a comparison with mechanical ligation of the rat coronary artery.
    Ikeda Y; Umemura K
    Methods Find Exp Clin Pharmacol; 2001; 23(1):23-8. PubMed ID: 11413860
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Clinical development of PEGylated recombinant staphylokinase (PEG-Sak) for bolus thrombolytic treatment of patients with acute myocardial infarction.
    Moreadith RW; Collen D
    Adv Drug Deliv Rev; 2003 Sep; 55(10):1337-45. PubMed ID: 14499711
    [TBL] [Abstract][Full Text] [Related]  

  • 51. New thrombolytic strategies.
    Van de Werf F
    Aust N Z J Med; 1993 Dec; 23(6):763-5. PubMed ID: 8141722
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Thrombolytic therapy.
    Baker WF
    Clin Appl Thromb Hemost; 2002 Oct; 8(4):291-314. PubMed ID: 12516680
    [TBL] [Abstract][Full Text] [Related]  

  • 53. [The artery responsible for an infarct after thrombolysis: to see or not?].
    Fernández Avilés F
    Rev Esp Cardiol; 1999 Feb; 52(2):103-4. PubMed ID: 10073091
    [No Abstract]   [Full Text] [Related]  

  • 54. Potential for a New Coronary Thrombolytic Plateau.
    Topol EJ
    J Thromb Thrombolysis; 1996; 3(2):127-134. PubMed ID: 10602553
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Coronary thrombolysis and the new biology.
    Sobel BE
    J Am Coll Cardiol; 1989 Oct; 14(4):850-60. PubMed ID: 2507611
    [No Abstract]   [Full Text] [Related]  

  • 56. Staphylokinase: a potent, uniquely fibrin-selective thrombolytic agent.
    Collen D
    Nat Med; 1998 Mar; 4(3):279-84. PubMed ID: 9500599
    [No Abstract]   [Full Text] [Related]  

  • 57. Coronary thrombolysis: some unresolved issues.
    Sobel BE; Bergmann SR
    Am J Med; 1982 Jan; 72(1):1-4. PubMed ID: 7058814
    [No Abstract]   [Full Text] [Related]  

  • 58. [New thrombolytic agents in myocardial infarction].
    Helft G; Elalamy I; Beygui F; Dambrin G; Lecompte T; Le Pailleur C; Le Feuvre C; Metzger JP; Vacheron A; Samama MM
    Arch Mal Coeur Vaiss; 1999 Apr; 92(4):411-7. PubMed ID: 10326149
    [TBL] [Abstract][Full Text] [Related]  

  • 59. [Increased efficacy of thrombolytic therapy in acute myocardial infarction by improved properties of new thrombolytic agents].
    Huber K
    Wien Klin Wochenschr; 2000 Sep; 112(17):742-8. PubMed ID: 11042902
    [TBL] [Abstract][Full Text] [Related]  

  • 60. New developments in thrombolytic therapy.
    Collen D; Gold HK
    Adv Exp Med Biol; 1990; 281():333-54. PubMed ID: 2129372
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.